Ital­ian AAV biotech clos­es $65M Se­ries A; GSK's Jem­per­li nabs pri­or­i­ty re­view in en­dome­tri­al can­cer

AA­Vant­garde, a Mi­lan-based AAV biotech, has closed a €61 mil­lion ($65.1 mil­lion) Se­ries A round.

The biotech cur­rent­ly has two AAV plat­forms, one us­ing DNA re­com­bi­na­tion and an­oth­er that trans-splices pro­teins, with treat­ment tar­gets in oph­thal­mol­o­gy. AA­Vant­garde is seek­ing to val­i­date its two lead plat­forms, tag­ging the funds for a proof-of-con­cept study and fur­ther de­vel­op­ment.

“This fi­nanc­ing rep­re­sents a hall­mark mo­ment in our mis­sion to help pa­tients and we are ex­cit­ed to work with both our new and found­ing in­vestors to ad­vance our plat­forms and pipeline. The com­ple­tion of this round with such a high-cal­iber group of glob­al life sci­ence in­vestors is a recog­ni­tion of the sig­nif­i­cance of AA­Vant­garde’s unique tech­nol­o­gy, which will ini­tial­ly be uti­lized to help pa­tients suf­fer­ing with the de­bil­i­tat­ing im­pact of blind­ness as­so­ci­at­ed with Ush­er1B syn­drome and Star­gardt dis­ease,” CEO Na­talia Mis­ci­at­tel­li said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER